The US drug regulator had conducted the inspections at the facility between May 26 and May 30.
“The company remains committed to maintain the highest standards of compliance,” it said in an exchange filing.
Additionally, the pharma company expects to stay on course to meet its 2030 revenue and margin targets, even as near-term uncertainty clouds the biotech funding environment.
While early-stage biotech funding remains uneven, demand for late-stage clinical development services continues to hold up well, Chairperson Nandini Piramal told CNBC-TV18 last month.
Piramal Pharma’s fourth quarter net profit increased 51.5% to ₹153.5 crore from the previous year’s ₹101.3 crore. Its revenue from operations increased 7.9% to ₹2,754 crore from ₹2,552 crore in the year-ago period.
Its earnings before interest, depreciation and amortisation (EBITDA) increased 5.9% to ₹561 crore in comparison to ₹529.9 crore in the previous fiscal. Its EBITDA margin stood at 20.45%
Shares of Piramal Pharma gained 1.5% on Monday, June 2. The stock was up 0.28% at ₹⟩206.88 apiece at 11.20 am . It has declined 24.35% in the last six months.
Also Read: Zydus Life gets tentative USFDA approval for tablets used to treat irritable bowel syndrome
